Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Addiction

Naltrexone not associated with serious adverse events, review finds

No significant difference in the rate of serious adverse events between naltrexone and placebo in licensed and unlicensed indications, say researchers.

The opioid antagonist naltrexone does not appear to increase the risk of serious adverse events over placebo, researchers from the University of Manchester have found[1].

The researchers carried out a systematic review and meta-analysis of 89 randomised controlled trials involving over 11,000 participants. Each of the trials were carried out for at least four weeks and examined the risk of adverse events with oral naltrexone compared with placebo.

Most trials considered the risks of naltrexone in its licensed indications, (i.e. alcohol use disorders and other addictions), but there were also studies on psychiatric disorders, impulse control disorders, Crohn’s disease and cancer. People taking opioids were excluded.

The results showed no significant difference in the rate of serious adverse events between naltrexone and placebo. Secondary analysis revealed only six marginally significant adverse events for naltrexone when compared with placebo, but these were of mild severity.

The researchers said that naltrexone is increasingly being used for off-label indications and may be taken by patients for long periods of time, so it was important to have clarity over its safety.

“These findings confirm the safety of oral naltrexone when used in licensed indications and encourage investments to undertake efficacy studies in unlicensed indications,” they concluded in BMC Medicine (15 January 2019).

Citation: Clinical Pharmacist DOI: 10.1211/CP.2019.20206174

Have your say

For commenting, please login or register as a user and agree to our Community Guidelines. You will be re-directed back to this page where you will have the ability to comment.

Recommended from Pharmaceutical Press

Search an extensive range of the world’s most trusted resources

Powered by MedicinesComplete
  • Print
  • Share
  • Comment
  • Save
  • Print Friendly Version of this pagePrint Get a PDF version of this webpagePDF

Jobs you might like

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.